Semmax Financial Advisors Inc. purchased a new stake in Emergent Biosolutions Inc (NYSE:EBS) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 506 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.
Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Emergent Biosolutions by 18.2% in the 3rd quarter. BlackRock Inc. now owns 6,350,905 shares of the biopharmaceutical company’s stock worth $418,078,000 after acquiring an additional 978,194 shares during the last quarter. Matarin Capital Management LLC acquired a new position in shares of Emergent Biosolutions in the 3rd quarter worth approximately $24,553,000. Neuberger Berman Group LLC acquired a new position in shares of Emergent Biosolutions in the 3rd quarter worth approximately $22,064,000. Lord Abbett & CO. LLC acquired a new position in shares of Emergent Biosolutions in the 4th quarter worth approximately $18,155,000. Finally, Vanguard Group Inc lifted its holdings in shares of Emergent Biosolutions by 6.7% in the 3rd quarter. Vanguard Group Inc now owns 4,603,209 shares of the biopharmaceutical company’s stock worth $303,029,000 after acquiring an additional 288,252 shares during the last quarter. 83.52% of the stock is owned by institutional investors and hedge funds.
In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 14,565 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $58.11, for a total value of $846,372.15. Following the sale, the chief executive officer now directly owns 142,617 shares of the company’s stock, valued at approximately $8,287,473.87. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Adam Havey sold 2,430 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $56.93, for a total transaction of $138,339.90. Following the completion of the sale, the executive vice president now directly owns 32,240 shares in the company, valued at $1,835,423.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,132 shares of company stock worth $3,411,113. 13.40% of the stock is owned by company insiders.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.14. The company had revenue of $270.70 million for the quarter, compared to analyst estimates of $269.05 million. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.61%. The firm’s quarterly revenue was up 39.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.74 EPS. Equities analysts expect that Emergent Biosolutions Inc will post 3.27 earnings per share for the current fiscal year.
Several equities analysts have recently commented on EBS shares. Wells Fargo & Co set a $68.00 price objective on shares of Emergent Biosolutions and gave the stock a “hold” rating in a report on Friday, March 1st. Cowen restated a “hold” rating and issued a $64.00 price objective on shares of Emergent Biosolutions in a report on Tuesday, November 20th. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. ValuEngine lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Finally, Cantor Fitzgerald set a $75.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Thursday, December 13th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $70.43.
Emergent Biosolutions Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Featured Article: Are all No-Load Funds Equal?
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.